卡培他滨联合甲酰四氢叶酸钙和奥沙利铂治疗进展期胃癌28例  

Capecitabine in combination with leucovorin and oxaliplatin as adjuvant chemotherapy in the treatment of advanced gastric cancer

作　　者：殷国建[1] 王少峰[1] 兰康华[1] 沈琼[1] 

机构地区：[1]苏州大学附属第二医院消化科,江苏省苏州市215004

出　　处：《世界华人消化杂志》2008年第6期671-674,共4页World Chinese Journal of Digestology

摘　　要：目的:观察卡培他滨(CAPE)联合甲酰四氢叶酸钙(LV)和奥沙利铂(OXA)化疗方案(CAPE- LV-OXA)治疗进展期胃癌(AGC)的临床疗效和毒副反应.方法:AGC患者28例接受CAPE-LV-OXA方案治疗,po LV 90 mg/d及CAPE 1250 mg/(m^2.d),d_(1-14);OXA85 mg/m^2,静脉滴注2h,d_1;每3wk为1个疗程.2-6个疗程后观察疗效及其不良反应.结果:可评价疗效25例,完全缓解0例,部分缓解13例,稳定7例,进展5例,有效率(RR)为52%(13/25),中位肿瘤进展时间(TTP)为5.4 (2-13)mo,中位生存时间(MST)为10.3(3-25) mo.毒副反应主要为胃肠道反应、骨髓抑制、手足综合征和黏膜炎等,多为Ⅰ-Ⅱ度毒性反应,所有Ⅲ度毒副反应4例,对症治疗或停止治疗后可缓解.无化疗相关死亡者.结论:CAPE-LV-OXA方案在AGC的治疗中疗效较为肯定,且耐受性良好.AIM：To evaluate the efficacy and toxicity of capecitabine in combination with leucovorin and oxaliplatin regimen（CAPE-LV-OXA）as the adjuvant chemotherapy in the treatment of patients with advanced gastric cancer. METHODS：Twenty-eight patients with advanced gastric cancer were enrolled in the study.Patients were administrated with oral capecitabine 1250 mg/（m^2·d）（d1-14）and oral leucovorin 90 mg/d（d1-14）,and intravenous oxaliplatin 85 mg/m^2（d1）in a 21-day cycle regimen for 2-6 cycles. RESULTS：Twenty-five patients were evaluable for efficacy and toxicity.There was no complete response,while 13 patients had partial responses,with an overall response rate of 52%.The median time to progression（TTP）was 5.4 months （range 2-13 months）.The median survival time was 10.3 months（range 3-25 months）.Therapy was generally well tolerated,and the most common adverse effects were gastrointestinal response,neutropenia,and hand-foot syndrome. There was no chemotherapy-related death. CONCLUSION：CAPE-LV-OXA regimen is an effective and well-tolerated chemotherapy regimen for advanced gastric cancer.

关 键 词：进展期胃癌 化疗 卡培他滨 奥沙利铂 甲酰四氢叶酸钙 

分 类 号：R735.2[医药卫生—肿瘤]